Knowledge Library

Cell Avidity
Filter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Cell Avidity measurements to understand and enhance CAR-T/tumor interactions in acute myeloid leukemia

Cell Avidity measurements to understand and enhance CAR-T/tumor interactions in acute myeloid leukemia

Webinar
January 1, 2020
01-01-20

CAR-T therapy can be a highly effective treatment for certain blood cancers such as acute myeloid leukemia (AML), but the mechanisms underlying productive CAR-T cell/tumor interactions are only beginning to be understood. Recent work has demonstrated that productive interactions can be influenced by the density of the target antigen on the tumor cell, stability of the CAR molecule itself, and additional antigen-independent and antigen-regulated interactions mediated by adhesion molecules. The sum total of the T-cell interaction with an antigen-bearing target cell is known as avidity.

Watch this webinar from Marcela Maus to learn about novel CARs and the use of avidity measurements to understand and enhance productive CAR-T cell interactions with both liquid and solid tumors.

Cell Avidity as a crucial biomarker for CAR T response

Cell Avidity as a crucial biomarker for CAR T response

Webinar
January 3, 2020
01-01-20

Liquid and solid tumors differ in their interactions with CAR T cells and it is important to understand the critical factors associated with tumor escape mechanisms. In this webinar, Dr. Rebecca Larson presented her work on “Loss of IFNγR signaling and downstream adhesion confers resistance to CAR T cell cytotoxicity in solid but not liquid tumors” in Nature, and suggests that enhancing binding interactions between T cells may yield improved responses in solid tumors. Learn how cell avidity measurements can improve CAR T cell response in solid tumors by identifying important evasion mechanism.

Enhanced avidity through combining a BCMA CAR and a CD38 chimeric co-stimulatory receptor leads to enhanced T cell sensitivity and persistence

Enhanced avidity through combining a BCMA CAR and a CD38 chimeric co-stimulatory receptor leads to enhanced T cell sensitivity and persistence

Webinar
January 4, 2020
01-01-20

B-cell maturation antigen (BCMA) is a potential target antigen in multiple myeloma due to its highly selective expression in malignant plasma cells. BCMA-targeted CAR T-cell therapy has been proven to be effective in patients with multiple myeloma. Despite that complete remission level reaching around 60-86%, a subset of patients still experience tumor relapse. Tumor escape due to low antigen density and limited efficiency in single-targeting BCMA CAR. In this webinar, Dr. Maria Themeli showed how to overcome low antigen density and improve CAR-T cell persistence with multi-targeting and co-stimulation through increasing synaptic avidity with the z-Movi.

Exploring the network of cellular interactions of Natural Killer cells in the tumor microenvironment with cell avidity

Exploring the network of cellular interactions of Natural Killer cells in the tumor microenvironment with cell avidity

Webinar
January 6, 2020
01-01-20

NK cells serve as a potential immunotherapeutic tool due to their innate ability to kill cancer cells. They play a crucial role in cancer prevention by providing immune surveillance, making them attractive candidates for immunotherapeutic tool. However, quite often NK cell can fail to recognize and eradicate residual cancer cells, resulting in cancer relapse and lower chance of survival. In this webinar, Prof. Mark Lowdell, Chief Scientific Officer of INmune Bio, Inc. discussed how primed NK cells become effective against resistant tumor cells, and how cell avidity measurements were used to depict a stronger binding of primed NK cells, resulting in improved tumor cell killing.

Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma

Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma

Webinar
October 19, 2020
01-01-20

Multiple myeloma is a cancer derived from malignant plasma cells. Conventional mono-targeting CAR T-cell therapies targeting BCMA have yielded remission in treated patients, however, a large proportion relapses due to BCMA antigen escape as a result of low antigen density. The development for effective CAR T-cell therapy with long-term remission is needed.

Learn from Prof. de Larrea how expressing two CARs on a single cell enhances the strength of CAR T-cell/target cell interactions, prevents BCMA escape-driven relapse, and how cell avidity measurements contributed to their findings in this webinar.

Unveiling a one-to-one relationship of TCR-dependent T cell function and cellular avidity at single-cell level using acoustic force

Unveiling a one-to-one relationship of TCR-dependent T cell function and cellular avidity at single-cell level using acoustic force

Webinar
November 18, 2020
01-01-20

TCR T cell therapy is a powerful tool that can redirect patients’ immune cells to target cancer cells. Conventional assays such as affinity measured by SPR do not always correlate with in vivo results, so the selected candidates might turn out not to be the best one. Our cell avidity expert, Dr. Will Singleterry, will present the insights cell avidity experiments provided for the team of Dr. Nathalie Rufer at University of Lausanne in this webinar.

TCR- and BsAb-induced interaction drives avidity-based cellular immunotherapy efficacy

TCR- and BsAb-induced interaction drives avidity-based cellular immunotherapy efficacy

Webinar
October 23, 2021
01-01-20

Bispecifc antibodies (bsAb) are molecules that can steer immune cells, such as T cells, NK cells, towards cancer cells. They facilitate the formation of the immunological synapses (IS), which are key driver of downstream T cell response. In this webinar, our principal scientist will show how cell avidity measures the effectiveness of the events during IS formation, and allow researchers to rank and select the best candidates.

How Cell Avidity between tumor-effector cell pairs drives the efficacy of cellular immunotherapy

How Cell Avidity between tumor-effector cell pairs drives the efficacy of cellular immunotherapy

Webinar
September 1, 2021
01-01-20

CAR-T cell therapy has increased in its popularity due to its robust nature and being MHC-independent. In this webinar, Dr. Rogier Reijmers, Principal Scientist at LUMICKS, will present several case studies and demonstrate how measuring Cell Avidity provides new insights by providing a more complete and physiologically relevant picture of the interaction between cells and their targets.

Cell avidity of CAR-NK cells revealed as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control

Cell avidity of CAR-NK cells revealed as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control

Webinar
February 1, 2023
01-01-20

Recent work using cell avidity measurements by the Gottschalk lab at St. Jude Children’s Research Hospital (published in Nature Biotechnology) sought to tune CAR synapses in NK cells by adding an intracellular scaffolding protein binding site to the CAR called the PDZ binding motif.

Improving CAR-T immunotherapy for lymphoma by fine-tuning avidity

Improving CAR-T immunotherapy for lymphoma by fine-tuning avidity

Webinar
July 16, 2024
01-01-20

Commercial CAR-T therapies still suffer from severe limitations, as majority of patients fail to achieve complete response and ultimately relapse.

Watch this Webinar to discover Prof. Marco Ruella’s team have adopted a novel CAR-T avidity screening method to improve safety and exhaustion profile, leading to 100% clinical response in a phase I trial.

Understanding the mechanism of action of a novel dual CAR approach with improved efficacy and safety using Cell Avidity

Understanding the mechanism of action of a novel dual CAR approach with improved efficacy and safety using Cell Avidity

Webinar
June 11, 2024
01-01-20

Acute myeloid leukemia (AML) continues to be an unmet clinical need for both adult and pediatric patients. Although CAR-T cell therapy has demonstrated substantial therapeutic potential, further advancements are necessary to achieve safe and lasting disease remission. In this webinar, CAR-CIK cell pioneer Dr. Sarah Tettamanti, from the Tettamnti foundation in Milan, Italy (alongside our Lead Product Manager, Shira Segal, at LUMICKS) discuss how Cell avidity was used to generate an additional layer of information to understand the mechanism of action and enhance decision-making on identifying the most efficacious candidates whilst limiting toxicity to healthy cells.

Text Link
Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers

Enhancing efficacy against clear cell renal cell carcinoma through format-tuning of bispecific T cell engagers

Scientific update
January 29, 2025
01-01-20

Text Link
Unlocking the Power of Memory-Like NK Cells using Cell Avidity: A New Frontier in Cancer Immunotherapy

Unlocking the Power of Memory-Like NK Cells using Cell Avidity: A New Frontier in Cancer Immunotherapy

Scientific update
November 18, 2024
01-01-20

Text Link
Cell Avidity uncovers critical binding mechanism impairing T-cell potency in the Tumor Microenvironment

Cell Avidity uncovers critical binding mechanism impairing T-cell potency in the Tumor Microenvironment

Scientific update
August 1, 2024
01-01-20

Text Link
Cell Avidity screening deployed by T cell pioneers to accelerate the identification of functional TCRs

Cell Avidity screening deployed by T cell pioneers to accelerate the identification of functional TCRs

Scientific update
June 25, 2024
01-01-20

Text Link
Cell Avidity-tuning ensures safe CAR-T therapy for solid tumors

Cell Avidity-tuning ensures safe CAR-T therapy for solid tumors

Scientific update
June 5, 2024
01-01-20

Text Link
From Handshakes to Hugs: Embracing the Dynamics of Immunological Synapse Strength and Avidity

From Handshakes to Hugs: Embracing the Dynamics of Immunological Synapse Strength and Avidity

Scientific update
January 17, 2024
01-01-20

Text Link
Measure interaction strength between target cell and TCR T-cell in HPV-related cancers with the z-Movi®

Measure interaction strength between target cell and TCR T-cell in HPV-related cancers with the z-Movi®

Scientific update
March 26, 2021
01-01-20

Text Link
Cell avidity is a superior predictor of CAR T-cell efficacy in myeloma than cytotoxicity – first published z-Movi®results

Cell avidity is a superior predictor of CAR T-cell efficacy in myeloma than cytotoxicity – first published z-Movi®results

Scientific update
July 29, 2020
01-01-20

Text Link
Screening of cancer targeting TCRs with the z-Movi®

Screening of cancer targeting TCRs with the z-Movi®

Scientific update
April 10, 2020
01-01-20

Text Link
The Scientist Magazine features z-Movi

The Scientist Magazine features z-Movi

Scientific update
January 25, 2019
01-01-20

Text Link
z-Movi featured in Science

z-Movi featured in Science

Scientific update
December 5, 2018
01-01-20

Text Link
Unraveling the Kinetics and Strength of T Cell Adhesion to Fibronecting using z-Movi®;

Unraveling the Kinetics and Strength of T Cell Adhesion to Fibronecting using z-Movi®;

Scientific update
October 2, 2018
01-01-20

Text Link
High-Throughput Label-free Cell Interaction Studies

High-Throughput Label-free Cell Interaction Studies

Scientific update
December 5, 2017
01-01-20

Cell Avidity measures true binding of biparatopic antibodies

Cell Avidity measures true binding of biparatopic antibodies

Application note
April 23, 2025
01-01-20

Mechanistic issues limit the effectiveness of many current cancer-targeting antibody therapies, with monospecific antibodies often hindered by receptor dimerization and activation. Biparatopic antibodies, which bind to two unique non-overlapping epitopes, offer a promising solution with stronger binding, more potent antagonism, and higher specificity.

Cell Avidity tackles on-target offtumor toxicity in novel CAR-T therapy

Cell Avidity tackles on-target offtumor toxicity in novel CAR-T therapy

Application note
April 23, 2025
01-01-20

Next generation chimeric antigen receptor (CAR) T-cell therapies hold promise in providing a curative solution for solid tumors. Nonetheless, the significant clinical hurdle of on-target off-tumor toxicity (OTOT) remains a major downside to the advancement of CAR T-cell therapies.

When Cell Avidity insights would have prevented clinical trial failure: the APRIL-CAR retrospective

When Cell Avidity insights would have prevented clinical trial failure: the APRIL-CAR retrospective

Application note
April 23, 2025
01-01-20

Interestingly, 8 out of 10 CAR T lead candidates fail after preclinical development. This suggests that current preclinical in vitro assays insufficiently predictive. This status quo could worsen as the field moves into tackling more challenging targets such as solid tumors, which require more sophisticated next generation designs like dual-targeting, logic-gating or BiTE-secreting CARs. However, implementing Cell Avidity analysis at an early stage in the drug development process can help to identify superior lead candidates and improve (pre)clinical correlation, as shown by this study.

Rapid assessment of CAR T cell strategies for multiple myeloma with the z-Movi Cell Avidity Analyzer

Rapid assessment of CAR T cell strategies for multiple myeloma with the z-Movi Cell Avidity Analyzer

Application note
June 5, 2020
01-01-20

Identifying effective immunotherapeutic treatment strategies for multiple myeloma that also mitigate relapse often requires tedious and time-consuming validations, such as cell-killing assays and in vivo engraftments. We show that intercellular binding strength (cell avidity), measured by the z-Movi® Cell Avidity Analyzer, quickly predicts CAR T-cell efficacies that correlate with treatment outcomes in vivo.

Identify functionally optimal TCR T cells through Cell Avidity measurements

Identify functionally optimal TCR T cells through Cell Avidity measurements

Application note
June 7, 2021
01-01-20

T cell receptor (TCR) -based cancer immunotherapy has the potential to become a powerful approach to treat solid tumors, such as melanoma. However, conventional methods that validate the effectiveness of TCR transduced T cells are often inconsistent with functional assays or are tedious to perform. In this application note, we show how the z-Movi® Cell Avidity Analyzer reliably and quickly identifies functionally optimal TCR-engineered T cells targeting melanoma cell lines based on cell–cell interaction strength (cellular avidity).

Accelerate your cell engager discovery with high throughput measurements of Cell Avidity

Accelerate your cell engager discovery with high throughput measurements of Cell Avidity

Application note
June 1, 2023
01-01-20

T cells play a pivotal role in tumor immunosurveillance. Multispecific cell engagers (CEs) have been adopted in the field of immuno-oncology to redirect T cells toward cancer cells, thereby unleashing the anti-tumor potential of the patient’s immune system. CE-mediated cell binding induces T cell activation and the formation of an immunological synapse, which is a prerequisite for effective tumor cell lysis.

The strength of the initial binding events between a T cell and a tumor cell dictates the efficiency of the anti-tumor response. Assessing cell avidity, i.e. the total intercellular interaction strength between two cells, gives crucial insights into the efficacy of CEs as anti-tumor therapeutic agents.

Here, we deploy LUMICKS’ high throughput avidity measurement (HTAM) technology to measure CE-induced cell avidity in a high throughput manner. We demonstrate the assay performance characteristics, i.e. specificity, precision, and range, via CE titration experiments in the context of a Jurkat T cell model system. We find that the HTAM CA assay is suitable for candidate screening in high throughput, with high sensitivity and precision.

Accelerate your cell engager discovery with high throughput measuremenets of Cell Avidity

Accelerate your cell engager discovery with high throughput measuremenets of Cell Avidity

Whitepaper
June 1, 2023
01-01-20

Cell Avidity: a key to accelerate IND filing in cell therapy drug development

Cell Avidity: a key to accelerate IND filing in cell therapy drug development

Whitepaper
July 1, 2023
01-01-20

z-Movi Product Brochure

z-Movi Product Brochure

Brochure
01-01-20

Avidigo Service Brochure

Avidigo Service Brochure

Brochure
May 1, 2025
01-01-20

Cell Avidity Technology Brochure

Cell Avidity Technology Brochure

Brochure
May 1, 2025
01-01-20

Avidion Product Brochure

Avidion Product Brochure

Brochure
April 8, 2025
01-01-20

There’s nothing here!
Try using a different combination of search criteria